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EUR. RESULTS: The overall prescribing of antiepileptics (N03)
within outpatient setting of Montenegro during investigated
period was 2.85 DTIDs, that was 232516.68 EUR. Although
combination of sodium-valproate and valproic acid was pre-
scribed approximately 13% (0.36 DTIDs), it participated in
total expenses extensively more (40.28%, 93661.92 EUR).
Newer antiepileptic agent, lamotrigin, was prescribed less than
4% (0.11 DTIDs), but It formed a one third of total costs
(€33.28%, €77,377.08). The expenses for the two most fre-
quently prescribed drugs phenobarbital and carbamazepine
were almost equal (€25,439.04 and €21,199.20, 20.06%),
although those drugs formed more than 80% of total prescrib-
ing. The participation of other drugs (sodium-valproate,
clonazepam, gabapentin) in total expenses was about
€14,839.44(6.38%). CONCLUSIONS: Our doctors mostly pre-
scribed older, accessible, long-term experienced and lower
priced antiepileptics. In order to fully estimate the expenses for
the pharmacological management of epilepsy is rational or not,
we have to explore this problem with more detail.
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OBJECTIVES: To evaluate the cost-effectiveness of ruﬁnamide
relative to topiramate and lamotrigine as adjunctive treatment
of Lennox-Gastaut Syndrome (LGS) a severe and devastating
form of childhood epilepsy. METHODS: A Markov state tran-
sition model was developed with 4 health states WC75, WC50,
NC (corresponding to 375%, 350% and <75%, and <50%
reduction in tonic-atonic (drop attack) seizure frequency respec-
tively) and “death”. Efﬁcacy and safety data were obtained
from the literature. Transition probabilities were derived from
patient level trial data for ruﬁnamide. In the absence of head to
head clinical studies, indirect/mixed treatment comparisons
were used to obtain efﬁcacy and safety estimates. LGS related
health state utilities were obtained from a utility study which
was carried out among the UK general public and caregivers/
parents using the time trade off (TTO) method and EQ-5D
questionnaires. Treatment beneﬁt, as reﬂected with percent of
patients achieving a given degree of reduction of drop-attack SF
over a three year horizon, were translated to quality adjusted
life years (QALYs). Medical resource and cost data were
obtained from an expert panel survey and published sources.
Costs were estimated from the perspective of the UK NHS and
personal social services. Probabilistic sensitivity analyses were
carried out. Cost and beneﬁts were discounted according to UK
guidelines. RESULTS: The primary base-case analysis using
TTO utilities found that, over 3 years, ruﬁnamide was associ-
ated with an incremental cost per QALY of £20,538 relative to
topiramate and £154,831 relative to lamotrigine. A secondary
analysis using EQ5D utilities found that ruﬁnamide was asso-
ciated with an incremental cost per QALY of £12,034 relative
to topiramate and £56,446 relative to lamotrigine. CONCLU-
SIONS: This study with its underlying assumptions and data
demonstrates that ruﬁnamide should be considered as a treat-
ment option for LGS, particularly as treatment choice is impor-
tant for this rare and devastating condition.
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OBJECTIVES: To estimate relapse-associated cost savings due to
reduction in MS-related hospitalization rates among natali-
zumab patients with relapsing multiple sclerosis (MS), including
those with highly-active disease. METHODS: A probabilistic
model was developed to estimate natalizumab-associated cost
savings based on reductions in annualized MS-related hospital-
ization rates due to relapse. Hospitalization rate data were
obtained from the randomized, double-blind, placebo-
controlled, phase 3, natalizumab monotherapy clinical trial
(AFFIRM). Among the 942 patients with relapsing MS who
received natalizumab 300 mg (n = 627) or placebo (n = 315)
intravenously for up to 116 weeks, those who reported 2
relapses in the prior year and 1 Gd+ enhancing lesions were
considered highly-active (n = 148 for natalizumab, n = 61 for
placebo). Natalizumab reduced the annualized MS-related hos-
pitalization rate by 65% (p < 0.001) among all patients (0.034
natalizumab vs 0.097 placebo) and by 89% (p < 0.001) among
those with highly-active disease (0.015 natalizumab vs 0.137
placebo). Cost savings associated with such reductions were
assessed using MS hospitalization costs obtained from a random
sample of the PharMetrics database ($19,750/episode, 2007 US
Dollars). The model ran 1,000 simulations to estimate the mean
costs of MS hospitalizations and associated 95% conﬁdence
intervals (CI). RESULTS: Due to relapse-associated hospitaliza-
tion rate reductions, the 2-year per-patient MS hospitalization
cost was $1,338 (95%CI: $842, $1964) for natalizumab and
$3828 (95%CI: $2628, $5281) for placebo, resulting in a cost
savings of $2490 (95%CI: $1,143, $3980). In patients with
highly-active disease, the 2-year per-patient MS hospitalization
cost was $604 (95%CI: $86, $1643) for natalizumab and $5436
(95%CI: $2558, $9593) for placebo, resulting in a cost savings
of $4832 (95%CI: $1988, $9111). CONCLUSIONS: Natali-
zumab signiﬁcantly reduced relapse-associated costs of
MS-related hospitalizations in patients with relapsing MS, with
the magnitude of reduction being even larger among those with
highly-active disease.
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OBJECTIVES: Narcolepsy is a disease resulting in excessive day-
time sleepiness (EDS) and cataplexy (an abrupt temporary loss of
voluntary muscular tone, sometimes evoked by an emotional
stimulus). Narcolepsy affects more than 20,000 people in the UK
and has many implications for health-related quality of life
(HRQL). The objective of our systematic review was to identify
and assess the suitability of instruments used to measure the
impact of narcolepsy on HRQL. METHODS: A systematic
search of Scopus (1966–2008) was conducted using terms syn-
onymous with “narcolepsy” combined with terms associated
with measuring “QoL”. Once the measures were identiﬁed,
further searches were undertaken to explore their use, develop-
ment history and demonstrated measurement properties.
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